anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for treating diabetic complications by administration of a beta-blocker is disclosed. Diabetic complications arise from diabetes and have few or no existing treatment options. The present invention describes the use of a beta-blocker in the treatment of a diabetic. The present invention also describes the inhibition of aldose reductase, one of the chief causative factors of diabetic complications. Also provided are methods of diabetic wound healing. Compositions for treating diabetic complications, such as diabetic wounds, are disclosed. The present invention includes employing a topical formulation of a beta-blocker, having substantially no antibacterial activity, to improve the process of diabetic wound healing. The present invention also involves increasing the rate of collagen accumulation of the healing epithelialized tissue in the wound of a diabetic individual.
The tolerability and safety of CARGPRC5D cells will be assessed according to the "3+3" doseescalation design.There will be three dose levels, 0.5×10\^6, 1.0×10\^6, 2.0x10\^6cells/kg. For each level, 3-6 subjects will be enrolled.
This is a single-center, single arm, open label study in senior men. This study will investigate the effect and tolerance of oral ingestion of Euryco-10. Subjects meeting all inclusion and none of the exclusion criteria will be enrolled and provided with study dietary supplement. Subjects will be instructed to take 2 capsules per day for 35 days. Administration and any adverse events will be recorded in the subject diary. At each clinic visit (Day 0, Day 21 and Day 35) the Subject will complete the AMS Questionnaire.
The present disclosure is related to the pharmaceutical industry in general and the pharmaceutical manufacturing industry for the treatment of diabetes and its complications. The advantages of the present invention with respect to state-of-the-art compositions, lies in that the present invention allows reducing both glycemia and micro and macro-vascular complications of the disease which are responsible in most cases of premature deaths from diabetes. The composition is formed by an antidiabetic and an antioxidant agent. The antidiabetic agent is metformin, while the antioxidant agent is Resveratrol. The metformin is present in the composition in an amount between 500 - 3000 mg, while resveratrol in an amount between 100 - 3000 mg. The combination may have any physical or pharmaceutical form.
BACKGROUND: As individuals age, they may develop Alzheimer's disease (AD), which is characterized by difficulties in speech, memory loss, and other issues related to neural function. Cycloastragenol is an active ingredient of Astragalus trojanus and has been used to treat inflammation, aging, heart disease, and cancer.
OBJECTIVES: This study aimed to explore the potential therapeutic benefits of cycloastragenol in rats with experimentally induced AD. Moreover, the underlying molecular mechanisms were also evaluated by measuring Nrf2 and HO-1, which are involved in oxidative stress, NFκB and TNF-α, which are involved in inflammation, and BCL2, BAX, and caspase-3, which are involved in apoptosis.
METHODS: Sprague-Dawley rats were given 70 mg/kg of aluminum chloride intraperitoneally daily for six weeks to induce AD. Following AD induction, the rats were given 25 mg/kg of cycloastragenol daily by oral gavage for three weeks. Hippocampal sections were stained with hematoxylin/ eosin and with anti-caspase-3 antibodies. The Nrf2, HO-1, NFκB, TNF-α, BCL2, BAX, and caspase-3 gene expressions and protein levels in the samples were analyzed.
RESULTS: Cycloastragenol significantly improved rats' behavioral test performance. It also strengthened the organization of the hippocampus. Cycloastragenol significantly improved behavioral performance and improved hippocampal structure in rats. It caused a marked decrease in the expression of NFκB, TNF-α, BAX, and caspase-3, which was associated with an increase in the expression of BCL2, Nrf2, and HO-1.
CONCLUSION: Cycloastragenol improved the structure of the hippocampus in rats with AD. It enhanced the outcomes of behavioral tests, decreased the concentration of AChE in the brain, and exerted antioxidant and anti-inflammatory effects. Antiapoptotic effects were also noted, leading to significant improvements in cognitive function, memory, and behavior in treated rats.
Data on the specific effects and bioequivalency of the different forms of estrogen are lacking, and in the young adolescent age group in particular, virtually non-existent. This has been complicated further by the difficulty in accurately interpreting estradiol assay results as the conventional radioimmunoassays (RIA) for estradiol are inaccurate and insensitive measuring very small concentrations in plasma. There is wide variation in the types of estrogens used for estrogen replacement, as well as doses and route of administration. Girls with Turner syndrome (TS) represent an important case study for these issues as they have early primary gonadal insufficiency or failure many years before the achievement of peak bone mass. Hence, a study of the effects of different estrogen compounds in this patient population offers a unique model that eliminates the confounding effects of other products produced by the intact gonad. Since in this condition it is imperative that estrogen replacement is started during the adolescent years and continued for several decades, this issue becomes highly relevant to these young women's health.Our specific aims are to: 1. to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) and relative biological potency of different oral vs. transdermal preparations of estradiol using state-of-the-art tandem mass spectrometry assays and recombinant cell bioassays; 2. to investigate the differential, long term metabolic effects of oral vs. transdermal estrogen replacement, specifically the effects on lipid and protein metabolism as well as body composition in this patient population; 3. to determine feasibility of estrogen concentration-based dosing in puberty and 4. To characterize the metabolic profile of TS girls previously treated with GH. To accomplish this we will study girls/young woman between ages 13 to 20 with TS in 2 protocols. Protocol #1 will be a study of the pharmacokinetic/pharmacodynamic (PK/PD) of 3 different preparations of estrogen in different doses. Protocol #2 will be a one year longitudinal study of the effects of oral vs. transdermal (TD) estrogen on body composition, hormones and growth factors.
We herein report a case of polyclonal hyperglobulinemia with multiple pulmonary cysts and nodules. The histopathological findings allowed us to speculate about the mechanism underlying cyst formation in these pathological conditions, which has not yet been thoroughly elucidated. The patient was a 49-year-old woman who presented with multiple pulmonary multilocular cysts and nodules. A lung biopsy revealed features of nodular lymphoid hyperplasia. Notably, lung structure fragmentation was evident, suggesting that structural destruction may have accompanied the disease during its course. The cysts were considered to have formed due to destruction of the lung structures.
Subarachnoid hemorrhage (SAH) is defined as sudden bleeding into the subarachnoid space. Although its incidence is low, mortality remains high. The most frequent cause of spontaneous SAH is aneurysm rupture. Cerebral CT scans are highly sensitive in ruling out SAH within the first 6 hours. Due to the recent improvement in imaging resolution, only a strong clinical suspicion can justify a cerebrospinal fluid analysis if the CT scan is normal after 6 hours. Cerebral MRI is also highly sensitive in both the acute and sub-acute phases. This article reviews the various clinical and paraclinical elements of the diagnostic approach, the main etiologies and the risk factors associated with SAH.
Circular RNA hsa_circ_0001322 (circ1322) was demonstrated to be significantly reduced in expression in gastric cancer patients in our previous study, and changes in its expression were significantly correlated with lymph node metastasis. However, the underlying workings of circ1322 in gastric cancer are still not fully understood. Therefore, to confirm the effect of circ1322 on gastric cancer, we examined the expression of circ1322 in gastric cancer cells and tissues. The results showed that circ1322 was lowly expressed in GC tissues and cells. Subsequently, we further performed cellular assays and animal experiments, which showed that Circ1322 upregulation inhibited GC cell proliferation, migration and invasion. while promoting GC cell apoptosis, and inhibited tumor growth in mice. The direct targeting of circ1322 to miR-1264 was confirmed by bioinformatics prediction and validation of luciferase reporter gene assay. Circ1322 can act as a miR-1264 sponge to alleviate the inhibitory effect of miR-1264 on its target gene, QKI. miR-1264 regulates the expression of QKI and the activity of the hedgehog pathway. That is, circ1322 may act as a competing endogenous RNA (ceRNA) to inhibit the hedgehog pathway by targeting the miR-1264/QKI axis, which in turn promotes GC progression.
An oral care implement is provided having a handle and a head with a soft tissue cleanser and/or tooth cleaning elements. The tooth cleaning elements may be flexibly mounted in the head for movement from an initial position with respect to the head during use. The soft tissue cleanser may include a plurality of projections for cleaning the soft tissue. The soft tissue cleanser may include a face having hills and valleys upon which the projections are located. The handle may include a base with a gripping region and a projection protruding from the base in the gripping region. The handle may also have a grip surface with a plurality of spaced slot openings exposing portions of the base. The grip body may form opposite finger grips on the handle.
The Control group will be placed in a chair for 30 minutes, within 60 minutes following either breakfast or lunch daily during admission, depending on other workflows in the ward. This corresponds to the time spent on exercise by the intervention group. The control group will also be in daily contact with the instructor following discharge and will be asked the same daily questions and will be seated in a chair for 30 minutes as during hospitalization.
PURPOSE: To evaluate whether geocoded social risk factor data predict the development of severe visual impairment or blindness due to glaucoma during follow-up using a large electronic health record (EHR) database.
DESIGN: Cohort study.
METHODS: Patients diagnosed with open-angle glaucoma (OAG) at a tertiary care institution. All eyes had glaucomatous visual field defects at baseline. Sociodemographic and ocular data were extracted from the EHR, including age, gender, self-reported race and ethnicity, insurance status, OAG type, prior glaucoma laser or surgery, baseline disease severity using Hodapp-Anderson-Parrish criteria, mean intraocular pressure (IOP) during follow-up, and central corneal thickness. Social vulnerability index (SVIndex) data at the census tract level were obtained using geocoded patient residences. Mixed-effects Cox proportional hazard models were completed to assess for the development of severe visual impairment or blindness during follow-up, defined as BCVA ≤ 20/200 at least at the last two clinic visits or standard automated perimetry (SAP) mean deviation (MD) ≤ -22dB confirmed on two tests.
RESULTS: A total of 4,046 eyes from 2,826 patients met inclusion criteria and were followed for an average of 4.3 ± 2.2 years. Severe visual impairment or blindness developed in 79 eyes (2.0%) from 76 patients (2.7%) after an average of 3.4 ± 1.8 years, leading to an incidence rate of severe visual impairment or blindness of 0.5% per year. Older age (adjusted hazards ratio [HR] 1.36 per decade, P = .007), residence in areas with higher SVIndex (HR 1.56 per 25% increase, P < .001), higher IOP during follow-up (HR 3.01 per 5 mmHg increase, P < .001), and moderate or severe glaucoma at baseline (HR 7.31 and 26.87, P < .001) were risk factors for developing severe visual impairment or blindness. Concordance index of the model was 0.88. Socioeconomic, minority status/language, and housing type/transportation SVIndex themes were key contributors to developing severe visual impairment or blindness.
CONCLUSIONS: Risk factors for developing glaucoma-related severe visual impairment or blindness included older age, elevated IOP during follow-up, moderate or severe disease at baseline, and residence in areas associated with greater social vulnerability. In addition to ocular risk factors, geocoded EHR data regarding social risk factors could help identify patients at high risk of developing glaucoma-related visual impairment.
The present invention relates to snail nutrition health oral liquid and a preparation method thereof. The snail nutrition health oral liquid is prepared from fresh snail meat, rice vinegar and honey. The present invention is characterized in that the snail nutrition health oral liquid also contains vegetative traditional Chinese medicines: dry barbary wolfberry fruit, dry chrysanthemum, dry snow lotus herb and dry lotus flower. The preparation technology of the snail nutrition health oral liquid of the present invention comprises the following steps: the rice vinegar extracting liquid of the fresh snail meat is prepared; the rice vinegar extracting liquid of the vegetative traditional Chinese medicines is prepared, and accordingly, the snail nutrition health oral liquid is prepared. The snail nutrition health oral liquid of the present invention contains more than 30 kinds of glusulase which is extracted from the snails, has bioactivity and also contains various biological active peptides extracted from snail nerves, various trace elements and various vitamins. The snail nutrition health oral liquid has the efficiency of wetting the throat, clearing away heat and toxic materials, dilating coronary arteries, lowering blood pressure, diluting blood fat, reducing blood sugar, protecting the liver, etc.
Ovarian cancer remains a formidable challenge in oncology due to its late-stage diagnosis and limited treatment options. Recent research has revealed the intricate interplay between glycan diversity and the immune microenvironment within ovarian tumors, shedding new light on potential therapeutic strategies. This review seeks to investigate the complex role of glycans in ovarian cancer and their impact on the immune response. Glycans, complex sugar molecules decorating cell surfaces and secreted proteins, have emerged as key regulators of immune surveillance in ovarian cancer. Aberrant glycosylation patterns can promote immune evasion by shielding tumor cells from immune recognition, enabling disease progression. Conversely, certain glycan structures can modulate the immune response, leading to either antitumor immunity or immune tolerance. Understanding the intricate relationship between glycan diversity and immune interactions in ovarian cancer holds promise for the development of innovative therapeutic approaches. Immunotherapies that target glycan-mediated immune evasion, such as glycan-based vaccines or checkpoint inhibitors, are under investigation. Additionally, glycan profiling may serve as a diagnostic tool for patient stratification and treatment selection. This review underscores the emerging importance of glycan diversity in ovarian cancer, emphasizing the potential for unraveling immune interplay and advancing tailored therapeutic prospects for this devastating disease.
<P>PROBLEM TO BE SOLVED: To provide a new agent for the treatment of melanogenesis insufficiency containing a highly safe kawapyrone derivative as an active component.  <P>SOLUTION: The agent for the treatment of melanogenesis insufficiency contains a kawapyrone derivative expressed by general formula (1) as an active component. In the formula, R<SP>1</SP>and R<SP>2</SP>are each a lower alkoxy, an arylalkyloxy, a substituent having esterified lower alkoxy group or a substituent having an esterified arylalkyloxy group. The agent for the treatment of melanogenesis insufficiency is used in the form of a skin lotion or an oral administration agent. The agent is suitable for the treatment of leukotrichia or leukoplakia.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE:The titled protecting drug containing an indole derivative or its acid addition salt as an active ingredient. CONSTITUTION:A drug for protecting gastrointestinal cell containing a compound (e.g., compound shown by the formula II, etc.) shown by the formula I (R<1> is lower alkyl; R<2> is lower alkylene) or its acid addition salt as an active ingredient. It is effective for remedying and preventing human or animal diseases of gastritis such as gastric ulcer, duodenal ulcer, and gastritis, Crohn's desease, inflammatory intestinal disease, infectious enteritis, colitis, ulceractive colitis, and intestinal inflammation of allergic or radiomedicinal diseases, etc. It has dosage forms such as tablet, capsule, granule, troche, syrup, emulsion, suppository, injection, etc. A dose is 10-2,000mg/persion/day, preferably 30-1,000mg/person/ day, and it may be administered be 2-4 times daily.
PURPOSE: To provide a method for locally delivering ibuprofen of medicine through skin in order to treat disease condition (inflammation and/or pain) of joint or parenchyma under skin. CONSTITUTION: This method for delivering ibuprofen through the skin to topically treat inflammation or pain comprises using an ibuprofen-containing hydroalcoholic gel of pH3.5 to 6.0 for topically treating inflammation or pain comprising an effective amount of ibuprofen, 40-60% alcohol, e.g. ethanol or isopropyl alcohol, 0-20% of a nonvolatile solvent, e.g. propylene glycol, 2.0 to 5.0% gelling agents, e.g. 2.5% hydroxypropyl cellulose or 4.0% polyacrylic acid polymer, sufficient base, e.g. triethanolamine, to adjust the pH to between 3.5 and 6.0 and water. Use of substantially pure S-ibuprofen to topically treat such inflammation or pain is provided.
Fatigue and balance disorders are common challenges experienced by Multiple Sclerosis (MS) individuals. The purpose of this study was to compare the concurrent effects of cerebellar and prefrontal anodal trans-cranial direct current stimulation (a-tDCS) with postural training on balance and fatigue in MS patients. 51 patients were evaluated to randomly allocation to a-tDCS over cerebellum, a-tDCS over dorsolateral prefrontal cortex (DLPFC) and sham group. 46 individuals (n = 16 in experimental groups and n = 14 in control group) followed treatment. All the groups received 10 sessions of postural training. The experimental groups underwent a-tDCS with a current of 1.5 mA for a period of 20 min. While, in the sham group, tDCS was only activated for 30 s and then turned off. The treatment included 10 sessions for four weeks. Before and after intervention, fatigue and balance were assessed using Fatigue Severity Scale (FSS), Timed Up and Go (TUG) test and Berg Balance Score (BBS), respectively. There was found a significant reduction in fatigue in the group receiving a-tDCS over the prefrontal cortex with postural training compared to the other two groups (P < 0.001). Additionally, a significant improvement was found in balance in the group receiving a-tDCS over the cerebellum concurrent with postural training in comparison to the other two groups (P < 0.001). Besides, in the sham group, the significant results were not reported in the variables. (P > 0.001). The results demonstrated that a-tDCS enhances the effects of postural training on balance and fatigue in MS patients.
The external focus group will receive 20 minutes of balance training 2 times per week. All training sessions will include a 5-minute walking warm-up, a 20-minute balance training program, and a 5-minute walking cool-down. The balance training will use a 30" wobble board with five bases ranging from 1" (easy) to 3" (very difficult). 20 trials of balance practice for 30-second intervals with 30-second breaks in between trials will be used every day. The external focus group will be reminded to focus their attention externally via the prompt "please keep the board as level as possible" prior to each balance trial. To monitor whether the experimental groups are focusing as asked and to what extent, a compliance check that has been used in similar attentional focus literature will be used.
A dentifrice in paste form comprises as abrasive constituent finely powdered mica in its natural crystalline lamellar form, together with the usual ingredients of toothpastes.  A list of suitable micas is given, those having a hardness of 2-3 being preferred.  Examples describe the incorporation of mica with an aqueous emulsion of soap, glycerine, and gum tragacanth, with glycerine and gum tragacanth mucilage, or with a solution of glycerine and gelatine with or without soap.  Antiseptics, astringents, perfumes, and colouring materials may be added.  The Specification as open to inspection under Sect. 91 comprises the use in a dentifrice of any powdered silicates having a hardness between 2 and 3.  Powdered asbestos is specified. Additional examples describe the incorporation of asbestos with the other ingredients specified above, and the preparation of a solid saponaceous dentifrice or a tooth powder containing mica or asbestos.  This subject-matter does not appear in the Specification as accepted.  Reference has been directed by the Comptroller to Specification 16490/84, [Class 91].
Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.
The efficacy of ENTRESTO was evaluated in a multinational, randomized, double-blind trial PANORAMA-HF comparing ENTRESTO (n = 187) and enalapril (n = 188) in pediatric patients aged 1 month to less than 18 years old due to systemic left ventricular systolic dysfunction (LVEF ≤ 45% or fractional shortening ≤ 22.5%). Patients with systemic right ventricle, single ventricle, restrictive cardiomyopathy or hypertrophic cardiomyopathy were excluded from the trial. Efficacy of ENTRESTO in patients less than 1 year old was not established. At Week 52, there were 144 ENTRESTO and 133 enalapril patients with a post-baseline assessment of NT-proBNP. The estimated least squares mean percent reduction from baseline in NT-proBNP was 65% and 62% in the ENTRESTO and enalapril groups, respectively. While the between-group difference was not nominally statistically significant, the reductions for ENTRESTO and enalapril were larger than what was seen in adults; these reductions did not appear to be attributable to post-baseline changes in background therapy.

Because ENTRESTO improved outcomes and reduced NT-proBNP in adults in PARADIGM-HF, the effect on NT-proBNP was the basis to infer improved cardiovascular outcomes in pediatric patients.